<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04829461</url>
  </required_header>
  <id_info>
    <org_study_id>CIS-023</org_study_id>
    <nct_id>NCT04829461</nct_id>
  </id_info>
  <brief_title>Effectiveness of Ambu® aScope™ 4 Cysto With the aView™ 2 Advance for Flexible Cystoscopy</brief_title>
  <official_title>Clinical Investigation to Evaluate the Effectiveness of the Ambu® aScope™ 4 Cysto With the Ambu® aView™ 2 Advance for Flexible Cystoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ambu Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ambu A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ambu A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the use of the single-use Ambu® aScope™ 4 Cysto for&#xD;
      removal of ureteral stents as compared to routine flexible reusable cystoscopes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, multi-center, post-market investigation of the&#xD;
      effectiveness of Ambu® aScope™ 4 Cysto (single-use cystoscope) as compared to routine&#xD;
      flexible reusable cystoscopes (standard of care) for ureteral stent removals. The&#xD;
      investigation will include approximately 102 subjects (randomized at a 1:1 ratio).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The success rate of the Ambu® aScope™ 4 Cysto and the Ambu® aView™ 2 Advance for stent removal procedures performed in the outpatient setting.</measure>
    <time_frame>Procedure Date (Day 0)</time_frame>
    <description>Stent removal procedural success rate with the Ambu® aScope™ 4 Cysto and the Ambu® aView™ 2 Advance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Ambu® aScope™ 4 Cysto and the Ambu® aView™ 2 Advance for stent removal procedures performed in the outpatient setting to standard of care reusable scopes on scope performance.</measure>
    <time_frame>Procedure Date (Day 0)</time_frame>
    <description>Comparison of Ambu® aScope™ 4 Cysto and the Ambu® aView™ 2 Advance for stent removal procedures performed in the outpatient setting to standard of care reusable scopes on scope performance as measured by procedure success rates, conversion rates, and device deficiency rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the Cumulative Procedure Time between the Ambu® aScope™ 4 cysto and the site's SOC reusable flexible cystoscope.</measure>
    <time_frame>Procedure Date (Day 0)</time_frame>
    <description>Comparison of the Cumulative Procedure Time between the Ambu® aScope™ 4 cysto and the site's SOC reusable flexible cystoscope as measured by:&#xD;
Scope preparation for procedure&#xD;
Actual procedure time (insertion of cystoscope to removal of cystoscope) and&#xD;
Time to dispose of or prepare for reprocessing of cystoscopy equipment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the user experience during cystoscopic procedures.</measure>
    <time_frame>Clinician Questionnaire; completed within one (1) day of procedure date (Day 0).</time_frame>
    <description>Clinician satisfaction rated on a five-point scale (1-5) with 5 being the better outcome.&#xD;
Ease of insertion&#xD;
Ability to visualize anatomical landmarks and/or urothelium changes&#xD;
Perception of image quality&#xD;
Maneuverability in the bladder&#xD;
Scope articulation with tools in the working channel&#xD;
Visualization while tools are in the working channel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoints</measure>
    <time_frame>7-10 Days Post-Procedure</time_frame>
    <description>Safety will be assessed based on the incidence rates of adverse events based on the seriousness and relatedness to the device and/or procedure.&#xD;
All reported device and/or procedural related adverse events through ten (10) days post-procedure&#xD;
All Serious Adverse Events (SAEs) through 10 days post-procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Cystoscopy</condition>
  <condition>Ureteral Stent</condition>
  <arm_group>
    <arm_group_label>Ambu® aScope™ 4 Cysto</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ureteral stent removal procedure performed with Ambu® aScope™ 4 Cysto (single-use cystoscope).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ureteral stent removal procedure performed with standard of care (reusable cystoscope).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ambu® aScope™ 4 Cysto with the aView™ 2 Advance used for stent removal</intervention_name>
    <description>Procedure using a single-use cystoscope for stent removal</description>
    <arm_group_label>Ambu® aScope™ 4 Cysto</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard of care reusable cystoscope used for stent removal</intervention_name>
    <description>Procedure using a reusable cystoscope for stent removal</description>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult (male or female), ≥18 years old&#xD;
&#xD;
          2. Patient undergoing routine flexible cystoscopy&#xD;
&#xD;
          3. Patient with a ureteral stent in the urinary system that is ready to be removed.&#xD;
&#xD;
          4. No active urinary tract infection&#xD;
&#xD;
          5. Subject is willing and able to sign informed consent and HIPAA authorization and&#xD;
             comply with requirements of the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of prior bladder/urethral reconstructive surgery.&#xD;
&#xD;
          2. History of high-grade bladder cancer or carcinoma in-situ of the bladder, undergoing&#xD;
             cystoscopy for follow-up/surveillance purposes.&#xD;
&#xD;
          3. Known unpassable urethral stricture&#xD;
&#xD;
          4. Febrile patient with active urinary tract infection (UTI)&#xD;
&#xD;
          5. Subjects with acute infection (acute urethritis, acute prostatitis, acute&#xD;
             epididymitis)&#xD;
&#xD;
          6. Subject with severe coagulopathy&#xD;
&#xD;
          7. Patient is unable to read and/or understand study requirements&#xD;
&#xD;
          8. Patient is unable or unwilling to provide written consent to participate in the study.&#xD;
&#xD;
          9. Subject, in the opinion of the Investigator, has a severe comorbidity, poor general&#xD;
             physical/mental health and/or a condition that will not&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Smith</last_name>
    <role>Study Director</role>
    <affiliation>Ambu Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timothy Coppa, MPH</last_name>
    <phone>+1 443 367 4532</phone>
    <email>timc@ambu.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Somadina Nwaokafor</last_name>
    <phone>+1 443 367 4536</phone>
    <email>sonw@ambu.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Pennsylvania State University and The Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Lehman</last_name>
      <phone>717-531-5930</phone>
      <email>Klehman3@pennstatehealth.psu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Suzanne Boltz</last_name>
      <phone>(717)-531-0003</phone>
      <phone_ext>284233</phone_ext>
      <email>sboltz@pennstatehealth.psu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jay Raman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonobia Garrett</last_name>
      <phone>214-645-8787</phone>
      <email>Sonobia.Garrett@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Brett Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Sund</last_name>
      <phone>608-265-0027</phone>
      <email>sund@ortho.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Sara Best, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Samplaski MK, Jones JS. Two centuries of cystoscopy: the development of imaging, instrumentation and synergistic technologies. BJU Int. 2009 Jan;103(2):154-8. doi: 10.1111/j.1464-410X.2008.08244.x. Epub 2008 Dec 8.</citation>
    <PMID>19076146</PMID>
  </reference>
  <reference>
    <citation>O'Sullivan DC, Chilton CP. Flexible cystoscopy. Br J Hosp Med. 1994 Apr 6-19;51(7):340-5. Review.</citation>
    <PMID>8081563</PMID>
  </reference>
  <reference>
    <citation>Pillai PL, Sooriakumaran P. Flexible cystoscopy: a revolution in urological practice. Br J Hosp Med (Lond). 2009 Oct;70(10):583-5. Review.</citation>
    <PMID>19966704</PMID>
  </reference>
  <reference>
    <citation>Gee JR, Waterman BJ, Jarrard DF, Hedican SP, Bruskewitz RC, Nakada SY. Flexible and rigid cystoscopy in women. JSLS. 2009 Apr-Jun;13(2):135-8.</citation>
    <PMID>19660204</PMID>
  </reference>
  <reference>
    <citation>Kadi N, Menezes P. ABC of flexible cystoscopy for junior trainee and general practitioner. Int J Gen Med. 2011;4:593-6. doi: 10.2147/IJGM.S20267. Epub 2011 Aug 19.</citation>
    <PMID>21887113</PMID>
  </reference>
  <reference>
    <citation>Miner N, Harris V, Lukomski N, Ebron T. Rinsability of orthophthalaldehyde from endoscopes. Diagn Ther Endosc. 2012;2012:853781. doi: 10.1155/2012/853781. Epub 2012 May 16.</citation>
    <PMID>22665966</PMID>
  </reference>
  <reference>
    <citation>Sokol WN. Nine episodes of anaphylaxis following cystoscopy caused by Cidex OPA (ortho-phthalaldehyde) high-level disinfectant in 4 patients after cytoscopy. J Allergy Clin Immunol. 2004 Aug;114(2):392-7.</citation>
    <PMID>15316522</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ureteral Stent</keyword>
  <keyword>aScope 4 Cysto</keyword>
  <keyword>single-use cystoscope</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

